Gibco™ TGFB1; Recombinant Human Protein

Descripción

Cell Therapy Systems CTS™ Recombinant Human TGF beta 1 (TGFB1) is a bioactive protein intended for use in cell culture applications, including pre-clinical and clinical cell therapy studies. TGFB1 acts synergistically with TGF-α in inducing transformation and acts as a negative autocrine growth factor. Dysregulation of TGFB1 activation and signaling may result in apoptosis. The lyophilized TGFB1 CTS™ Recombinant Human is verified for activity through dose-dependent inhibition of proliferation of mouse HT-2 cells stimulated with mouse IL-4.

• Qualified—helps reduce your burden in qualifying reagents for regulatory submission in cell therapy applications
• Highly Pure—minimizes interference from other proteins or contaminants
• Active—get more results with less protein

Simplified Transition into Clinical Research

GIBCO™ Cell Therapy Systems (CTS™) products are of high quality and supplied with harmonized documentation such as Certificates of Analysis, Certificates of Origin, and access to authorization letters for our Drug Master Files, as appropriate. The GIBCO™ CTS™ product line enables you to reduce your burden in qualifying reagents during your transition from research applications to clinical applications.

High Purity

To help verify that GIBCO™ CTS™ Recombinant growth factors are of the highest quality, each protein is analyzed for purity, along with structural homogeneity, to help ensure a biologically active protein. The purity of each GIBCO™ CTS™ recombinant growth factor is verified by SDS-PAGE to be over 95% pure and to have endotoxin levels below 0.1 ng/μg.

High Biological Activity

All GIBCO™ CTS™ Recombinant growth factors are verified for activity. Each lot has its own ED50 determined using an activity assay based on a specific function of the growth factor. The activity of our TGFB1 CTS™ Recombinant Human growth factor is determined by the dose-dependent inhibition of proliferation of mouse HT-2 cells stimulated with mouse IL-4 to have an ED50 ≤0.2 ng/mL. Optimal concentration for individual applications should be determined by a dose response assay.